Drug intelligence / Profile preview

RGC-COV19

Development stage
Preclinical
Lead developer
Regencell
Administration
Oral
01

Overview

**RGC-COV19** is an investigational, orally administered liquid formula developed by Regencell Bioscience using natural ingredients based on Traditional Chinese Medicine (TCM) principles. It is designed to treat mild to moderate COVID-19 symptoms by stimulating the body's own healing mechanisms, specifically to reduce and clear mucus and phlegm from the upper respiratory system, dispel exterior viral pathogens via heavy sweats, urine, and excrement, clear endogenous and liver heat, detoxify the liver, and improve body circulation. In the EARTH efficacy trial involving 37 patients, 97.3% had symptoms eliminated within a 6-day treatment period (except sensory dysfunction and occasional cough), with 83.8% reporting elimination of one or more symptoms after one full dose; no adverse events, hospitalizations, or deaths were reported, and efficacy was consistent across demographics, vaccination status, and comorbidities.[1][2][6]

Brand names
RGC-COV19RGC-COV-19RGC-COV 19

Beyond the preview

Go deeper on RGC-COV19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGC-COV19.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call